<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Souha S Kanj, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Pseudomonas aeruginosa
         </em>
         , a gram-negative nonfermenting bacillus, is a much-feared pathogen. The organism is common in the environment, especially in water, even contaminating distilled water [
         <a href="#rid1">
          1,2
         </a>
         ]; it is also an important cause of infections associated with hot tubs and contaminated contact lens solutions [
         <a href="#rid3">
          3,4
         </a>
         ]. Considerable attention is paid to
         <em>
          P. aeruginosa
         </em>
         as a potential pathogen in hospitals because:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is often found in water in sinks and can contaminate respiratory equipment, which can serve as an environmental reservoir, especially in intensive care units (ICUs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The organism displays a predilection for infecting immunocompromised hosts, including burn patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          P. aeruginosa
         </em>
         is the most serious pathogen causing ventilator-associated pneumonia (VAP).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          P. aeruginosa
         </em>
         strains with resistance to multiple antibiotics have become common in some hospitals and regions.
        </p>
        <p>
        </p>
        <p>
         The epidemiology and pathogenesis of infections due to
         <em>
          P. aeruginosa
         </em>
         will be reviewed here. The clinical manifestations, diagnosis, and treatment of infections due to this organism are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2136.html" rel="external">
          "Pseudomonas aeruginosa bacteremia and endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">
          "Pseudomonas aeruginosa skin and soft tissue infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20477480">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         was first isolated from green pus by Gessard in 1882. It is a nonfermentative gram-negative aerobic rod that is ubiquitous in the environment and can be grown on a variety of media. The following features are helpful in confirming its identification on culture plates:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Characteristic sweet, grape-like odor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elaboration of green pigment  (
         <a class="graphic graphic_picture graphicRef77055" href="/z/d/graphic/77055.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxidase-positive
        </p>
        <p>
        </p>
        <p>
         Occasionally, identification by laboratory personnel may be delayed because some isolates lack pigments or produce unusual characteristics such as a "rotten potato" odor [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         is often an opportunistic pathogen, causing infections in patients with physical, phagocytic, or immunologic defects in host defense mechanisms. Historically,
         <em>
          P. aeruginosa
         </em>
         has been a major burn wound pathogen, a serious cause of bacteremia in neutropenic patients, and the most important pathogen in cystic fibrosis (CF) patients. However, these associations have undergone considerable change, with a shift in the spectrum of the hosts who are now commonly infected by
         <em>
          P. aeruginosa
         </em>
         .
        </p>
        <p>
         <em>
          P. aeruginosa
         </em>
         is a common cause of health care-associated infections among the general population [
         <a href="#rid6">
          6-9
         </a>
         ]. According to data reported to the National Healthcare Safety Network (NHSN) in the United States from 2018 to 2022,
         <em>
          P. aeruginosa
         </em>
         was the fifth most common cause of hospital-acquired infections. It was consistently found among the top pathogens from multiple anatomic sites; it was the second most common cause of ventilator-associated pneumonia (VAP), the third most common cause of catheter-associated urinary tract infection (CAUTI), and the tenth most common cause of catheter-related bloodstream infection (CLABSI) in adults admitted to acute care hospitals [
         <a href="#rid6">
          6,7
         </a>
         ]. It is also a common pathogen globally; it was the third most common cause of bloodstream infections according to a SENTRY antimicrobial surveillance program that collected data from sites in 45 countries worldwide [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Patterns of antimicrobial resistance have geographical variation. (See
         <a class="local">
          'Prevalence of resistance'
         </a>
         below.)
        </p>
        <p>
         Apart from causing human infections,
         <em>
          P. aeruginosa
         </em>
         is also an important plant pathogen, affecting tobacco, tomatoes, and lettuce; it can be found in most fresh water environments, including moist areas in hospitals.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Neutropenia and burns
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with neutropenia
         </strong>
         – Since the early 1980s, the role of
         <em>
          P. aeruginosa
         </em>
         in infections in febrile neutropenic patients has diminished in Western Europe and North America. This organism previously accounted for one-third to one-half of gram-negative bacteremia in these patients but has become a much less frequent pathogen in this setting. As an example, in a single-centered retrospective study from China,
         <em>
          P. aeruginosa
         </em>
         accounted for only 3.5 percent of all gram-negative bacterial isolates from neutropenic patients with bacteremia [
         <a href="#rid10">
          10
         </a>
         ]. However,
         <em>
          P. aeruginosa
         </em>
         remains one of the most common causes of gram-negative bacteremia among neutropenic patients with malignancy in certain locations, such as Japan and Spain [
         <a href="#rid11">
          11,12
         </a>
         ], and an increasing proportion of isolates from such patients are carbapenem-resistant strains [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="local">
          'Prevalence of resistance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with burn injury
         </strong>
         – Similarly,
         <em>
          P. aeruginosa
         </em>
         was previously the single most important cause of burn wound sepsis and infectious deaths following burns, but there has been a reduction in infections due to this organism since the 1980s. However,
         <em>
          P. aeruginosa
         </em>
         continues to be an important cause of both bacteremia and recurrent bacteremia in combat-related burn casualties [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The reasons for the above trends are not entirely clear, although the use of empiric antibiotic regimens with antipseudomonal activity may play a role. Furthermore, it is likely that incidence of
         <em>
          Pseudomonas
         </em>
         infection in subpopulations of patients, such as patients with neutropenia and burn injury, is highly complex and related to acquisition and host factors that are poorly understood. (See
         <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">
          "Overview of neutropenia in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">
          "Drug-induced neutropenia and agranulocytosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia", section on 'Mechanisms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         is the most common pathogen isolated from adults with CF [
         <a href="#rid16">
          16
         </a>
         ]. It is also the most common cause of respiratory failure in CF and is responsible for the deaths of the majority of these patients [
         <a href="#rid17">
          17
         </a>
         ]. With time, however, its relative prevalence seems to have declined. Retrospective analyses of the data reported to the CF Foundation Patient Registry (CFFPR) found a significant decrease in overall incidence and prevalence of
         <em>
          P. aeruginosa
         </em>
         from 2003 to 2012 [
         <a href="#rid18">
          18,19
         </a>
         ]. In a more recent CFFPR report the percentage of respiratory cultures positive for
         <em>
          P. aeruginosa
         </em>
         had declined from 55.1 percent in 2006 to 28.4 percent in 2021 [
         <a href="#rid20">
          20
         </a>
         ]. This decreasing trend might be explained by improved infection control and strategies focusing on early eradication of the pathogen. One other explanation is the introduction of disease-modifying therapy such as
         <a class="drug drug_general" data-topicid="17144" href="/z/d/drug information/17144.html" rel="external">
          ivacaftor
         </a>
         , as some studies have compared respiratory cultures in patients taking ivacaftor versus those who are not, revealing a reduction in both
         <em>
          P. aeruginosa
         </em>
         infection and acquisition [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pseudomonas aeruginosa'
         </a>
         .)
        </p>
        <p>
         Acquisition of
         <em>
          P. aeruginosa
         </em>
         in patients with CF begins early in childhood (median one year) [
         <a href="#rid17">
          17
         </a>
         ]. It is believed that the organism is initially acquired from environmental sources, but patient-to-patient spread may also occur in clinics and households [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         .)
        </p>
        <p>
         Over time, a number of mutations occur in
         <em>
          P. aeruginosa
         </em>
         in the CF lung environment that promote persistence of the organism. In one study, for example, 11 of 30 CF patients were colonized with a hypermutable strain of
         <em>
          P. aeruginosa
         </em>
         that persisted for years in most cases; such hypermutable strains were not isolated from patients with acute
         <em>
          P. aeruginosa
         </em>
         infection who did not have CF [
         <a href="#rid25">
          25
         </a>
         ]. These hypermutable strains tend to be multidrug-resistant [
         <a href="#rid25">
          25,26
         </a>
         ] and accumulate over time, often with the loss of virulence traits [
         <a href="#rid26">
          26
         </a>
         ]. Interestingly, these adaptations are associated with reduced organism survival in a typical environmental habitat, such as tap water [
         <a href="#rid26">
          26
         </a>
         ]. Nonmutated strains with maintained virulence represent a minority of organisms.
        </p>
        <p>
         The initial acquisition of
         <em>
          P. aeruginosa
         </em>
         in the CF lung is with nonmucoid strains and occurs early in life (median one year) [
         <a href="#rid17">
          17
         </a>
         ]. Over time (median 11 years), there is a transition to a mucoid phenotype that is associated with deterioration in cough scores, chest radiograph scores, and pulmonary function.
        </p>
        <p>
         Clinical and in vitro data suggest synergism between respiratory syncytial virus (RSV) infections and
         <em>
          P. aeruginosa
         </em>
         in CF lung disease [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Health care-associated infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         is among the most common causes of VAP and carries the highest mortality among hospital-acquired infections [
         <a href="#rid28">
          28
         </a>
         ]. As an example, in a multicenter study from intensive care units (ICUs) in hospitals from 56 countries,
         <em>
          P. aeruginosa
         </em>
         was the most commonly isolated gram-negative respiratory pathogen (25 percent of 7171 isolates) [
         <a href="#rid29">
          29
         </a>
         ]. The frequency and morbidity of
         <em>
          P. aeruginosa
         </em>
         health care-associated pneumonia are unchanged despite infection control policies that aimed to control this serious complication of medical therapy. (See
         <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">
          "Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"
         </a>
         .)
        </p>
        <p>
         <em>
          Pseudomonas
         </em>
         is also a frequent cause of health care-associated bacteremia [
         <a href="#rid30">
          30-32
         </a>
         ], wound, and urinary tract infections, with occasional involvement of other sites following surgery (eg, gram-negative meningitis, sternal osteomyelitis) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Studies of the molecular epidemiology of
         <em>
          P. aeruginosa
         </em>
         isolated from ICU patients have shown that most infections are endemic with high clonal diversity involving both antibiotic-resistant and relatively susceptible isolates [
         <a href="#rid34">
          34
         </a>
         ]. However, "epidemic high-risk clones" can also spread among hospitalized patients.
        </p>
        <p>
         Outbreaks of
         <em>
          P. aeruginosa
         </em>
         have occurred as a result of faulty or unclean medical equipment or products, environmental reservoirs (eg, colonized sink faucets), and cross-contamination within the hospital [
         <a href="#rid35">
          35-38
         </a>
         ]. One of the largest outbreaks involved 231 patients in 24 hospitals in Norway; the major clinical manifestations were pneumonia and sepsis [
         <a href="#rid35">
          35
         </a>
         ]. The cause of the outbreak was contamination of moist mouth swabs. The in-hospital mortality rate was 31 percent, occurring only in patients with severe underlying disease. Contamination of medical equipment may also cause pseudo-outbreaks, as illustrated by a report of isolation of extremely drug-resistant
         <em>
          P. aeruginosa
         </em>
         from the urine of both hospitalized and ambulatory patients due to contamination of an automated urine analyzer [
         <a href="#rid39">
          39
         </a>
         ]. These reports highlight the importance of the environmental cleaning component of infection control in preventing such infections. (See
         <a class="medical medical_review" href="/z/d/html/101613.html" rel="external">
          "Infection prevention: General principles", section on 'Health care environment: Cleaning and disinfection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1530910587">
         <span class="h3">
          Secondary infections in patients with COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         is a common cause of secondary bacterial infections in individuals hospitalized with COVID-19 [
         <a href="#rid40">
          40-44
         </a>
         ]. In a systematic review of 30 studies including 3834 patients, 7 percent of hospitalized COVID-19 patients had a bacterial infection, and
         <em>
          P. aeruginosa
         </em>
         was the second most common, identified in 12 percent of secondary infections [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Among critically ill patients with COVID-19,
         <em>
          P. aeruginosa
         </em>
         is an important cause of VAP, as it is in the general ICU population. In a study of 50 patients with COVID-19 who required extracorporeal membrane oxygenation (ECMO), 86 percent developed VAP, 37 percent of which were caused by
         <em>
          P. aeruginosa
         </em>
         ;
         <em>
          P. aeruginosa
         </em>
         was the predominant cause of recurrent VAP in this series [
         <a href="#rid43">
          43
         </a>
         ]. Bloodstream infections with
         <em>
          P. aeruginosa
         </em>
         have also been reported in critically ill patients with COVID-19 [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         In a more recent systematic review evaluating 49 studies including 21,2605 participants from 2020 to 2022, the pooled prevalence of bacterial coinfections (defined as coinfection, secondary infection, and super infection) was 26.84 percent showing an increase in the trend of coinfection, 11 percent of which were secondary to
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Studies evaluating the incidence of
         <em>
          P. aeruginosa
         </em>
         bloodstream infection have yielded conflicting results, with some reporting an increase while others reporting a decrease. Two recent systematic reviews evaluating the literature on this topic found a slight increase in
         <em>
          P. aeruginosa
         </em>
         infections during the pandemic; however, no concrete numbers were provided [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Community-acquired infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has been increasing recognition of
         <em>
          P. aeruginosa
         </em>
         as a cause of community-acquired infections, including folliculitis (due to hot tubs, whirlpools, or contaminated sponges) [
         <a href="#rid3">
          3,48,49
         </a>
         ], pneumonia [
         <a href="#rid50">
          50
         </a>
         ], puncture wound osteomyelitis [
         <a href="#rid51">
          51
         </a>
         ], endocarditis in injection drug users [
         <a href="#rid52">
          52,53
         </a>
         ], otitis externa after swimming in fresh water lakes [
         <a href="#rid54">
          54
         </a>
         ], peritonitis or exit site infection in patients undergoing continuous ambulatory peritoneal dialysis [
         <a href="#rid55">
          55-57
         </a>
         ], and community-acquired bacteremia and pneumonia in patients with AIDS [
         <a href="#rid58">
          58,59
         </a>
         ].
        </p>
        <p>
         <em>
          P. aeruginosa
         </em>
         is also an important pathogen in patients with bronchiectasis, many of whom eventually harbor multidrug-resistant
         <em>
          P. aeruginosa
         </em>
         as their final pathogen. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Antibiotics for prevention of exacerbations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1864320089">
         <span class="h1">
          ANTIMICROBIAL RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The fact that
         <em>
          P. aeruginosa
         </em>
         is both intrinsically resistant to a number of antibiotics and can acquire resistance during therapy contributes to its bacterial virulence.
        </p>
        <p>
         The NHSN evaluates the antibiotic resistance rates of
         <em>
          P. aeruginosa
         </em>
         isolates according to the type of infection [
         <a href="#rid60">
          60
         </a>
         ]. In a report spanning from 2018 to 2021 [
         <a href="#rid7">
          7
         </a>
         ], the overall rate of multi-drug resistant (MDR) isolates in hospital-acquired infections was found to be 11.9 percent. According to the infection site in acute care hospitals, the rates were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2.9 percent for superficial surgical site infections, 3.9 percent for deep incisional surgical site infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         15.4 percent in VAP
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         8.7 percent in hospital wards compared to 10.6 percent in ICUs in CAUTIs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         11.9 percent in hospital wards compared to 14.2 percent in ICUs in CLABSI
        </p>
        <p>
        </p>
        <p>
         After years of declining resistance, the COVID-19 pandemic seems to have exacerbated antibiotic resistance in
         <em>
          P .aeruginosa
         </em>
         . The CDC special report on antimicrobial resistance in COVID-19 reported an increase in MDR
         <em>
          P. aeruginosa
         </em>
         by 32 percent compared to 2019 [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H340045430">
         <span class="h2">
          Mechanisms of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of mechanisms of antibiotic resistance in
         <em>
          P. aeruginosa
         </em>
         have been described. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AmpC beta-lactamase [
         <a href="#rid62">
          62,63
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extended-spectrum beta-lactamase (ESBLs) [
         <a href="#rid64">
          64,65
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Downregulation of the outer membrane protein OprD, a carbapenem-specific porin [
         <a href="#rid66">
          66,67
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multidrug efflux pumps [
         <a href="#rid68">
          68-72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability of the organism to form a biofilm [
         <a href="#rid73">
          73,74
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Possible transfer of a 16S rRNA methylase gene from Actinomycetes [
         <a href="#rid75">
          75
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Acquired resistance, specifically, can result from mutation or acquisition of exogenous resistance determinants and can be mediated by a number of mechanisms, including degrading enzymes, reduced permeability, and active efflux [
         <a href="#rid64">
          64,76
         </a>
         ].
        </p>
        <p>
         With respect to degrading enzymes, plasmid-mediated ESBLs have been described at a limited number of geographic sites. TEM, SHV, and CTX-M ESBLs have been reported in
         <em>
          P. aeruginosa
         </em>
         , but are uncommon; VEB ESBLs are prevalent in the species in East Asia and are now scattered elsewhere, and PER types are widespread in Turkey. These enzymes confer high-level resistance to antipseudomonal cephalosporins, and some, such as PER-1, also degrade cephems and monobactams [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/469.html" rel="external">
          "Extended-spectrum beta-lactamases"
         </a>
         .)
        </p>
        <p>
         The potential impact of PER-1 was illustrated in a series of 26
         <em>
          P. aeruginosa
         </em>
         bloodstream infections (BSIs) from Siena, Italy [
         <a href="#rid64">
          64
         </a>
         ]. Nine expressed PER-1 and the other 17 did not express any ESBL. Seven of the nine PER-1 BSIs failed to respond to antibiotic therapy, including carbapenems. In comparison, only 4 of 14 non-ESBL BSIs failed to respond, including only one of eight treated with a carbapenem.
        </p>
        <p>
         Resistance to carbapenems, particularly
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , can arise by simple mutation resulting in the loss of a carbapenem-specific porin, OprD [
         <a href="#rid65">
          65
         </a>
         ]. Less often, metallo-beta-lactamases (MBLs) are responsible: VIM and IMP MBLs have been reported internationally, whereas clones with SPM-1 enzymes have disseminated in Brazil. Some have caused major outbreaks, with dozens to hundreds of patients affected over prolonged periods. (See
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)"
         </a>
         .)
        </p>
        <p>
         Multidrug resistance in
         <em>
          P. aeruginosa
         </em>
         is believed to be secondary to efflux pumps on the bacterial surface. One study demonstrated that the addition of an efflux inhibitor in vitro decreased the minimum inhibitory concentrations (MICs) of
         <em>
          P. aeruginosa
         </em>
         isolates to various antibiotics by twofold or more [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In view of the variability in defining multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) in the medical literature, the European Center for Disease Prevention and Control (ECDC) as well as the United States Centers for Disease Control and Prevention (CDC) joined efforts in 2012 in order to establish a standardized international definition for these terminologies in multiple organisms, including
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid78">
          78
         </a>
         ]. They were defined as follows:
        </p>
        <p>
         MDR: non-susceptibility to at least one agent in three or more antimicrobial categories.
        </p>
        <p>
         XDR: non-susceptibility to at least one agent in all but two or fewer antimicrobial
        </p>
        <p>
         categories (ie, bacterial isolates remain susceptible to only one or two categories).
        </p>
        <p>
         PDR: non-susceptibility to all agents in all antimicrobial categories.
        </p>
        <p>
         In 2018, Kadri et al proposed a new terminology, "difficult-to-treat" organisms, in other terms, organisms that are non-susceptible to first-line antibiotics (ie, intermediate or resistant to all reported agents in the carbapenems, beta-lactams, and fluoroquinolones categories) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1590804377">
         <span class="h2">
          Prevalence of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patterns of antibiotic resistance in
         <em>
          P. aeruginosa
         </em>
         evolve over time and vary geographically and by type of infection. This geographical variation highlights the importance of local epidemiological data when choosing empiric therapy.
        </p>
        <p>
         As an example, in North America from 2005 to 2010, resistance to fluoroquinolones among intra-abdominal and urinary tract infection isolates increased (from 22 to 33 percent); resistance to
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         (20 percent) and other beta-lactams (
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , and
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ; 23 to 26 percent) remained essentially unchanged; and resistance to
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         declined (from 11 to 3 percent) [
         <a href="#rid80">
          80
         </a>
         ]. Resistance patterns were different in other locations: in South Africa, resistance to piperacillin-tazobactam was 8 percent and to cefepime, ceftazidime, and imipenem was 25 to 26 percent; in China, resistance rates to amikacin and piperacillin-tazobactam were 12 and 8 percent, respectively. Among the countries of the Arab league, the highest prevalence of carbapenem-resistant
         <em>
          P. aeruginosa
         </em>
         occurred in Jordan (93 percent), followed by Algeria and Egypt (56 and 50 percent, respectively) [
         <a href="#rid81">
          81
         </a>
         ]. In one study of 38 isolates from a burn-care hospital in Azerbaijan, there were high levels of resistance to all classes of antibiotics except
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         and
         <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">
          polymyxin B
         </a>
         , and 63 percent of the isolates were carbapenem resistant [
         <a href="#rid82">
          82
         </a>
         ].
         <em>
         </em>
         A study of over 6000 isolates from the Asia-Pacific region found that approximately 40 percent of isolates were either carbapenem-resistant or MDR; India had the highest rates of carbapenem resistance (29 percent) [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         In the United States, surveillance suggests a trend toward declining rates of resistance, although rates still remain high [
         <a href="#rid60">
          60
         </a>
         ]. Among catheter-related BSI, catheter-associated urinary tract infection (CAUTI), and VAP isolates, resistance ranged from 22 to 26 percent for extended-spectrum cephalosporins, 16 to 19 for
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         , 30 to 33 percent for fluoroquinolones, 24 to 28 percent for carbapenems, and 17 to 23 percent for aminoglycosides. Approximately 18 to 19 percent were MDR. Rates of resistance were generally lower (4 to 11 percent) among surgical site infection isolates.
        </p>
        <p>
         Resistance to newer beta-lactam/beta-lactamase inhibitors (BL-BLIs), such as
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         , and
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         , appears to be uncommon in the United States. In a study of over 3100 isolates from 71 hospitals from 2020 to 2021, susceptibilities were as follows: ceftazidime-avibactam 97.0 percent, ceftolozane-tazobactam 98.0 percent, and imipenem-relebactam 97.3 percent [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         In Europe, antibiotic resistance is highly variable across countries, with studies demonstrating a high incidence of MDR and extensively drug-resistant (XDR)
         <em>
          P. aeruginosa
         </em>
         among patients with VAP in Greece, Italy, and Spain [
         <a href="#rid85">
          85
         </a>
         ]. Resistance rates are especially high in Greece, where up to 89 percent of isolates were MDR, XDR, or pan-drug resistant. A European study of over 580 respiratory isolates revealed susceptibility rates of 95.5 percent to
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         , 94.3 percent to
         <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">
          imipenem-cilastatin-relebactam
         </a>
         , and 93.3 percent to
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         ; susceptibility rates were significantly lower in Eastern Europe than Western Europe [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         In a recent systematic review based on 78 studies assessing the global rate of resistance of multiple pathogens to
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         , the prevalence of nonsusceptibility in
         <em>
          P. aeruginosa
         </em>
         was found to be low (1.4 percent), even in carbapenem-resistant isolates (3.5 percent) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         Resistance to first-line beta-lactam antibiotics has been associated with higher rates of resistance to the newer BL-BLIs. In a multicenter study of gram-negative respiratory isolates from ICU patients from over 200 hospitals in 56 countries, 38 percent of
         <em>
          P. aeruginosa
         </em>
         isolates were not susceptible to
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , and 34 percent were not susceptible to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ]. Among isolates nonsusceptible to all three agents, 62 to 68 percent remained susceptible to
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         .
        </p>
        <p>
         The use of locally-derived antibiograms to predict susceptibility of individual antibiotics to
         <em>
          P. aeruginosa
         </em>
         may not be as reliable for patients who become infected during long hospital stays. In one study involving 3393 isolates of
         <em>
          P. aeruginosa
         </em>
         from a single tertiary care hospital, the utility of the hospital’s antibiogram dropped as the length of time from admission to recovery of
         <em>
          P. aeruginosa
         </em>
         increased [
         <a href="#rid88">
          88
         </a>
         ]. In another study, the most important predictors of MDR
         <em>
          P. aeruginosa
         </em>
         infections among hospitalized patients were the number of prior antibiotics received, history of infection within the preceding three months, hospital prevalence of MDR strains, and complicated urinary tract infection [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Different strategies for administering antibiotics have been considered to overcome the increasing resistance patterns, including high-dose prolonged infusions of beta-lactams. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/97446.html" rel="external">
          "Prolonged infusions of beta-lactam antibiotics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individual strains often contain numerous virulence factors, more than those encountered in other pathogens, such as group A streptococcus and
         <em>
          Staphylococcus aureus
         </em>
         .
         <em>
          P. aeruginosa
         </em>
         is capable of expressing a large number of toxins and surface components associated with virulence [
         <a href="#rid90">
          90-92
         </a>
         ]. While each of these toxins and surface components show a deleterious effect in cell lines or even in an animal model, the role of many of these putative virulence factors remains unproven in humans.
        </p>
        <p>
         In contrast to most other bacteria,
         <em>
          P. aeruginosa
         </em>
         has two modes of virulence expression, resulting in at least two forms of distinct pathogenetic behavior:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some strains remain confined to the lungs as a chronic, indolent colonizer (as occurs in many patients with CF).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other strains can invade tissues, causing pneumonia or bacteremia along with their potential complications of septic shock and death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Chronic infection in cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies that have serially examined both the bacterial diversity and load of the microbial flora in the lower respiratory tract of patients with CF demonstrated that bacterial diversity typically decreases as the severity of illness increases even though the total bacterial load remains relatively stable [
         <a href="#rid93">
          93
         </a>
         ].
         <em>
          P. aeruginosa
         </em>
         are present as part of the resident microbial flora in the lower respiratory tract of most patients with CF, and in some patients,
         <em>
          P. aeruginosa
         </em>
         becomes the dominant organism as the severity of CF illness progresses.
        </p>
        <p>
         Most patients with CF eventually die from respiratory failure because of a gradual loss of lung function. This loss of function is a consequence of decades of continuous colonization with
         <em>
          P. aeruginosa
         </em>
         and inflammation triggered by the host response to the organism [
         <a href="#rid94">
          94
         </a>
         ]. It may be argued that there is no expression of virulence in this setting and that the inflammation is simply a bystander reaction by the host to the presence of an organism in the airways. However, the fact that
         <em>
          P. aeruginosa
         </em>
         persists in the airways to the exclusion of most other bacteria suggests that there is active expression of specific genes to maintain this tropism. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Infection'
         </a>
         .)
        </p>
        <p>
         A detailed, whole-genome analysis of
         <em>
          P. aeruginosa
         </em>
         isolates from a CF patient during eight years of infection found that virulence factors that are required for the initiation of acute infections are selected against during subsequent chronic infection [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H784419753">
         <span class="h3">
          Early airway colonization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial infection is generally acquired from the environment, although person-to-person transmission is also a plausible source [
         <a href="#rid95">
          95
         </a>
         ]. There are at least three possible mechanisms allowing early airway colonization with
         <em>
          P. aeruginosa
         </em>
         in patients with CF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following initial acquisition,
         <em>
          P. aeruginosa
         </em>
         has a propensity to attach to cells via pili and flagella, resulting in an initial infection [
         <a href="#rid96">
          96
         </a>
         ]. This hypothesis suggests that there are more pilus receptors on CF cells or that there is a greater response to pilin binding than on normal airway cells [
         <a href="#rid97">
          97
         </a>
         ]. Piliated organisms or purified pili lead to the production of interleukin-8 on airway epithelial cells; in one study, this response was four times higher in a CF cell line [
         <a href="#rid96">
          96
         </a>
         ]. This attachment is thought to induce goblet cell hyperplasia and consequently mucus hyper-secretion, contributing to CF pathology [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A CF transmembrane conductance regulator (CFTR) may function as a cellular receptor for
         <em>
          P. aeruginosa
         </em>
         that
         <em>
         </em>
         facilitates phagocytosis and clearance of the organism from the airways. Patients with CF may lack CFTR or express a mutant CFTR that prevents phagocytosis and clearance from the airway. In an in vitro study, murine cells expressing recombinant human wild-type CFTR ingested 30 to 100 times as many
         <em>
          P. aeruginosa
         </em>
         organisms as cells lacking CFTR or those expressing the mutant delta F508 CFTR protein seen in many patients with CF [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The airways of patients with CF commonly manifest mucous hypersecretion and a defect in mucociliary clearance that progressively worsens with age;
         <em>
          P. aeruginosa
         </em>
         is able to bind to mucous in airways and thus is protected from phagocytosis [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite having most of its virulence factors downregulated once the infection becomes chronic,
         <em>
          P. aeruginosa
         </em>
         uses some virulence factors to establish a niche allowing for chronic infection as well as contributing to CF pathology [
         <a href="#rid22">
          22
         </a>
         ]. In fact, elastase was found to decrease residual CFTR activity and expression and also to inhibit airway healing through degradation of interleukin-6 [
         <a href="#rid102">
          102
         </a>
         ]. Furthermore, pyocyanin was found to inhibit ciliary beating as well as modulate mucin glycosylation, allowing for higher affinity to
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         Of note, some studies have observed that isolates in CF patients with newly identified
         <em>
          P. aeruginosa
         </em>
         infection frequently have mucoid- and biofilm-forming phenotypes, which are more classically associated with adaptation towards chronic persistence in the CF lung [
         <a href="#rid104">
          104,105
         </a>
         ]. (See
         <a class="local">
          'Persistence of the organism in the airways'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Persistence of the organism in the airways
         </span>
         <span class="headingEndMark">
          —
         </span>
         An examination of
         <em>
          P. aeruginosa
         </em>
         organisms isolated from this chronic state of colonization in patients with CF frequently shows the following abnormalities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Downregulation of the production of toxins [
         <a href="#rid106">
          106
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of lipopolysaccharides "O" side chains [
         <a href="#rid107">
          107
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expression of an alginate coat that probably protects against phagocytosis [
         <a href="#rid108">
          108,109
         </a>
         ] (see
         <a class="local">
          'Mucoid phenotype'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequent loss of the flagellum and pili [
         <a href="#rid110">
          110,111
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Conventional wisdom about pathogenesis states that pathogens produce diseases by expressing their virulence factors. There are two possible explanations for downregulation of virulence factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The immunologic response to virulence factors within colonizing strains of
         <em>
          P. aeruginosa
         </em>
         selects for survival of strains that have mutated to phenotypes that evade the host immune mechanisms in the lungs. The observation that
         <em>
          P. aeruginosa
         </em>
         flagellin synthesis is downregulated in the CF lung could represent an adaptive response by the organism to avoid detection by host defense mechanisms, as flagellin is highly immunogenic and subject to detection by host pattern recognition receptors [
         <a href="#rid112">
          112
         </a>
         ]. Exposure of
         <em>
          P. aeruginosa
         </em>
         to reactive oxygen species by neutrophils is thought to be the principal mechanism that causes DNA damage allowing for mutations involved in the chronicity of the infection [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Virulence factors may no longer be needed for chronic colonization, and they disappear from strains colonizing the airways because of random mutations in the genes responsible for their expression.
        </p>
        <p>
        </p>
        <p>
         Although mutations such as those discussed above could explain why host defenses do not eradicate the organisms, it is probable that organisms with a normal phenotype are able to persist in the face of intact host defense mechanisms early in the life of many patients with CF. Thus, the best explanation for persistence may be defects in mucociliary clearance and in host killing of bacteria in CF.
        </p>
        <p class="headingAnchor" id="H9635348">
         <span class="h4">
          Decreased bacterial killing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of studies have suggested that the lungs of patients with CF have defective mechanisms for bacterial killing. This may be related in part to the high chloride concentrations in pulmonary secretions [
         <a href="#rid113">
          113
         </a>
         ]. Defects in bacterial killing induced by a high chloride environment include inactivation of beta-defensins, which are antimicrobial peptides secreted by respiratory epithelia [
         <a href="#rid114">
          114,115
         </a>
         ], increased release of inflammatory mediators by neutrophils, and diminished neutrophil killing [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         However, such defects in patients with CF do not explain the preferential selection of
         <em>
          P. aeruginosa
         </em>
         as a pathogen over other bacteria. The predisposition to
         <em>
          Pseudomonas
         </em>
         infection in patients with CF may be due in part to impaired clearance directly related to defects in CFTR discussed above [
         <a href="#rid99">
          99,117
         </a>
         ]. For example, treatment with
         <a class="drug drug_general" data-topicid="17144" href="/z/d/drug information/17144.html" rel="external">
          ivacaftor
         </a>
         , which restores functioning of the CFTR protein, is associated with reduced
         <em>
          P. aeruginosa
         </em>
         culture positivity [
         <a href="#rid118">
          118
         </a>
         ]. Similarly, CFTR-knockout mice have an impaired ability to control
         <em>
          Pseudomonas
         </em>
         lung infections characterized by increased binding of
         <em>
          P. aeruginosa
         </em>
         to respiratory epithelial cells, an effect that can be reversed by CFTR gene transfer [
         <a href="#rid119">
          119,120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9635371">
         <span class="h4">
          Biofilm formation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biofilm or microcolony formation in
         <em>
          P. aeruginosa
         </em>
         facilitates persistence of the organism in the airways of patients with CF. Organisms contained in biofilms are resistant to antibiotic treatment, which in turn facilitates persistence in airways [
         <a href="#rid121">
          121
         </a>
         ]. As an example, in a study of CF patients with newly identified
         <em>
          P. aeruginosa
         </em>
         airway infection, wrinkly colony surface and irregular colony edges (phenotypes previously implicated in increased biofilm formation and aberrant quorum sensing) were associated with persistence following antibiotic treatment [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         An in vitro study of
         <em>
          P. aeruginosa
         </em>
         showed that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation [
         <a href="#rid122">
          122
         </a>
         ]. A
         <em>
          P. aeruginosa
         </em>
         gene (aminoglycoside response regulator [arr]) was essential for this induction and contributed to biofilm-specific aminoglycoside resistance. Biofilm formation can be a specific defensive reaction to the presence of antibiotics: a mechanism that may be responsible for the differences in therapeutic outcome in CF patients treated with
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         aerosols. (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         .)
        </p>
        <p>
         Epigallocatechin-3-gallate, a bioactive ingredient of traditional green tea, appears to have an inhibitory effect in vitro on the development of biofilm, protease and elastase activity, and swimming and swarming motility of
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9635378">
         <span class="h4">
          Mucoid phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         During prolonged colonization,
         <em>
          P. aeruginosa
         </em>
         isolates often convert to a mucoid phenotype through production of the polysaccharide alginate  (
         <a class="graphic graphic_picture graphicRef56963" href="/z/d/graphic/56963.html" rel="external">
          picture 2
         </a>
         ). Alginate production contributes to biofilm growth, decreased clearance by host immune responses, and tissue damage [
         <a href="#rid124">
          124
         </a>
         ]. One study demonstrated that alginate production was increased when the organisms were present in the relatively anaerobic environment of CF mucous [
         <a href="#rid125">
          125
         </a>
         ]. This mucoid phenotype is seen infrequently in non-CF populations, but occurs in over 75 percent of
         <em>
          P. aeruginosa
         </em>
         isolated from patients with CF. Opsonic antibodies produced by the host in CF are unable to kill these mucoid organisms [
         <a href="#rid126">
          126
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
         Females with CF are colonized with mucoid
         <em>
          P. aeruginosa
         </em>
         more frequently and earlier in chronic infection than males. Estrogen production appears to be directly related to this finding, as illustrated by a study in which exposure to estrogens induced alginate production in a nonmucoid strain of
         <em>
          P. aeruginosa
         </em>
         in vitro [
         <a href="#rid127">
          127
         </a>
         ]. In vivo, mucoid strains of
         <em>
          P. aeruginosa
         </em>
         were isolated more frequently during times of high estradiol production in six women with CF who were sampled throughout their menstrual cycles. Furthermore, among 23 women, mucoid
         <em>
          P. aeruginosa
         </em>
         accounted for 63 percent of strains isolated from pulmonary CF exacerbations that occurred during the follicular (high estradiol) phase of the menstrual cycle. In contrast, no strains isolated from exacerbations during the luteal phase (low estradiol) had the mucoid phenotype. Pulmonary exacerbations were also observed more frequently during the follicular phase.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Interactions with other pathogens
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           S. aureus
          </em>
         </strong>
         –
         <em>
          P. aeruginosa
         </em>
         may also promote
         <em>
          S. aureus
         </em>
         colonization in the lungs of patients with CF. An exoproduct of
         <em>
          P. aeruginosa
         </em>
         (HQNO) protects
         <em>
          S. aureus
         </em>
         from killing by aminoglycosides and selects for small-colony variants of
         <em>
          S. aureus
         </em>
         that have stable aminoglycoside resistance and persist in chronic infection [
         <a href="#rid128">
          128
         </a>
         ]. HQNO can be detected in the sputum of CF patients infected with
         <em>
          P. aeruginosa
         </em>
         but not in uninfected patients. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Progression of pulmonary disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Stenotrophomonas maltophilia
          </em>
         </strong>
         – Infections with
         <em>
          P. aeruginosa
         </em>
         appear
         <em>
         </em>
         to promote colonization and coinfection with
         <em>
          S. maltophilia
         </em>
         . In a mouse model, coinfection with
         <em>
          P. aeruginosa
         </em>
         and
         <em>
          S. maltophilia
         </em>
         resulted in higher
         <em>
          S. maltophilia
         </em>
         counts from bronchoalveolar lavage and lung tissue specimens than
         <em>
          S. maltophilia
         </em>
         monoinfection, likely because the two organisms formed well-integrated biofilms
         <em>
         </em>
         [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Acute invasive P. aeruginosa infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         possesses an array of virulence factors implicated in acute infections [
         <a href="#rid130">
          130
         </a>
         ]. These include secreted products; exotoxins A, S, and U; elastase; alkaline protease; cytotoxins; phospholipase C; and phenazines [
         <a href="#rid131">
          131-133
         </a>
         ]. Cell-bound organelles (such as pili and flagella) and membrane-bound lipopolysaccharide (LPS, endotoxin) have also been implicated in virulence.
        </p>
        <p>
         There is no single product that explains the organism's ability to cause disease and death. In an in vitro study, biofilm formation and distribution of virulence genes did not appear to differ between VAP and non-VAP isolates, although VAP isolates were less virulent in an in vivo model [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p>
         A reasonable synthesis of the experimental work in this area is that different virulence factors play a role at different stages in the pathogenesis of invasive infections.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Invasion
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         requires an intact flagellum and motility to exert its maximum invasive effect in some animal models of infection. Strains lacking flagella are less capable of causing bacteremia and pneumonia in neonatal mice [
         <a href="#rid135">
          135
         </a>
         ] and of disseminating from burn wounds [
         <a href="#rid136">
          136,137
         </a>
         ].
        </p>
        <p>
         The relative importance of the motility function of flagella and a possible proinflammatory role of flagellin were examined in a lung model of acute
         <em>
          P. aeruginosa
         </em>
         infection [
         <a href="#rid138">
          138
         </a>
         ]. The findings suggested that flagellin is involved in early mortality, while loss of motility alone did not appear to affect virulence. Thus, the decreased virulence in strains lacking flagella in the neonatal mouse model cited above is more likely due to the absence of flagellin [
         <a href="#rid135">
          135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Lipopolysaccharide and toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         After invasion, lipopolysaccharide (LPS) probably plays a role in disease similar to that proposed for other gram-negative pathogens. LPS protects the organism from the activity of complement in the bloodstream and triggers cytokine pathways, leading to sepsis and septic shock. (See
         <a class="medical medical_review" href="/z/d/html/1597.html" rel="external">
          "Pathophysiology of sepsis"
         </a>
         .)
        </p>
        <p>
         In addition to LPS, it has been proposed that the elaboration of toxins after invasion is responsible for some of the tissue damage. The role of toxins in the disease process has been difficult to determine, as there are no data incriminating a specific toxin, such as is found with diphtheria toxin or the staphylococcal and streptococcal shock toxins. In addition, mutants of
         <em>
          P. aeruginosa
         </em>
         lacking many of these toxins remain virulent.
        </p>
        <p>
         Thus, although toxins are probably not needed for the major disease syndromes encountered in most patients with
         <em>
          P. aeruginosa
         </em>
         infections, they may play a role in some localized infections, such as in the eye [
         <a href="#rid139">
          139
         </a>
         ] or lung [
         <a href="#rid119">
          119,140
         </a>
         ], and contribute to the severity of disease. This potential effect was illustrated in a study of
         <em>
          P. aeruginosa
         </em>
         strains isolated from 108 consecutive patients with lower respiratory or systemic infection [
         <a href="#rid140">
          140
         </a>
         ]. Infection with a
         <em>
          P. aeruginosa
         </em>
         strain expressing the type III secreted toxins (TTSS; eg, ExoS, ExoT, ExoU, ExoY, or PcrV) was associated with a sixfold greater risk of death compared with infection with a strain that did not express these proteins (odds ratio 6.2). ExoU, which disrupts the integrity of the lipid membrane, is associated with cytotoxicity, severe lung epithelial injury, and bacterial dissemination. The severity of lung epithelial injury and the risk of bacterial dissemination into the circulation correlate with the ExoU phenotype in different
         <em>
          P. aeruginosa
         </em>
         strains [
         <a href="#rid141">
          141
         </a>
         ]. ExoY induces edema and might elicit amyloid cytotoxins that subvert the endothelial amyloid host defense; in has been associated with end-organ dysfunction in ventilated patients with
         <em>
          P. aeruginosa
         </em>
         lung infection [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
         Expression of these type III secreted toxins is associated with higher mortality in patients with
         <em>
          P. aeruginosa
         </em>
         bacteremia as well [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
         The degree of infection may be limited by host factors. Experimental data suggest that host ubiquitin ligase Cbl-b limits
         <em>
          P. aeruginosa
         </em>
         dissemination mediated by the secreted toxin ExoT [
         <a href="#rid143">
          143
         </a>
         ]. Ubiquitination leads to proteasomal degradation of the toxin.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Investigational interventions based on pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Part of the impetus for studies of pathogenesis in
         <em>
          P. aeruginosa
         </em>
         infections is interest in the development of a vaccine to prevent infection in susceptible hosts or new antimicrobials for treatment of the organism. No vaccines or new antibiotics have yet resulted from this work, but development of vaccines against type III secretion system proteins [
         <a href="#rid144">
          144
         </a>
         ], LPS [
         <a href="#rid145">
          145
         </a>
         ], and flagella [
         <a href="#rid146">
          146
         </a>
         ] continues. Quorum sensing (QS), a regulation mechanism that dictates the expression of some virulence factors and biofilm formation was recently investigated as a potential therapeutic modality; some FDA-approved medications (eg,
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         ) have shown ability to inhibit this mechanism in in vivo studies [
         <a href="#rid147">
          147,148
         </a>
         ]. Other research has focused on phage therapy [
         <a href="#rid149">
          149
         </a>
         ], neutralizing antibodies against exotoxins [
         <a href="#rid150">
          150
         </a>
         ], and live attenuated vaccines from
         <em>
          Francisella
         </em>
         or
         <em>
          Salmonella
         </em>
         strains, but these interventions remain experimental and incompletely studied [
         <a href="#rid151">
          151,152
         </a>
         ]. Although vaccine candidates against outer-membranes OprF-OprI conjugates initially yielded promising results in healthy volunteers as well as burn patients [
         <a href="#rid153">
          153,154
         </a>
         ], they unfortunately were not able to reduce infection rate despite displaying a significant immunogenic effect [
         <a href="#rid155">
          155
         </a>
         ]. Plasmapheresis to remove inhibitory antibodies has also been explored [
         <a href="#rid156">
          156
         </a>
         ]. Public availability of the
         <em>
          Pseudomonas
         </em>
         genome sequence may provide further insights into the mechanisms of pathogenesis of
         <em>
          P. aeruginosa
         </em>
         infections and help investigators discover new genetic targets that can be exploited for vaccine or therapeutic development [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19299002">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Environmental niche
         </strong>
         –
         <em>
          Pseudomonas aeruginosa
         </em>
         , a nonfermenting gram-negative bacillus, is prevalent in the environment, particularly in water, which can serve as a reservoir for infection. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Certain features are characteristic of
         <em>
          P. aeruginosa
         </em>
         grown on culture and help confirm its identification. These include a sweet grape-like odor, elaboration of green pigment, and oxidase-positivity. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         –
         <em>
          P. aeruginosa
         </em>
         is a common cause of nosocomial pneumonia, urinary tract infection, and surgical site infection. It has become a less frequent cause of bacteremia in patients with neutropenia in most parts of the world. It remains the most important pathogen in patients with cystic fibrosis.
         <em>
          P. aeruginosa
         </em>
         is also associated with certain community-acquired infections following particular exposures (eg, water, puncture wounds, injection drug use). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cystic fibrosis
         </strong>
         – In patients with cystic fibrosis, chronic colonization with
         <em>
          P. aeruginosa
         </em>
         is associated with a downregulation of virulence factors and expression of a mucoid phenotype that likely protects against phagocytosis and opsonization.
         <em>
          P. aeruginosa
         </em>
         may also promote
         <em>
          Staphylococcus aureus
         </em>
         colonization in the lungs of patients with cystic fibrosis. (See
         <a class="local">
          'Chronic infection in cystic fibrosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resistance
         </strong>
         –
         <em>
          P. aeruginosa
         </em>
         can develop resistance to antibiotics through a number of mechanisms, including expression of beta-lactamases or efflux pumps and downregulation of outer membrane porins. (See
         <a class="local">
          'Antimicrobial resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1420756685">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel Sexton, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Warburton DW, Bowen B, Konkle A. The survival and recovery of Pseudomonas aeruginosa and its effect upon salmonellae in water: methodology to test bottled water in Canada. Can J Microbiol 1994; 40:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science 1971; 173:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman AR, Nieland ML. Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis. J Am Acad Dermatol 1983; 8:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson LA, Schlitzer RL, Ahearn DG. Pseudomonas corneal ulcers associated with soft contact-lens wear. Am J Ophthalmol 1981; 92:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labarca JA, Pegues DA, Wagar EA, et al. Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa. Clin Infect Dis 1998; 26:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 2020; 41:1.
          </a>
         </li>
         <li class="breakAll">
          HAI Pathogens and Antimicrobial Resistance Report, 2018-2021. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nhsn/hai-report/data-tables-adult/index.html (Accessed on November 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diekema DJ, Hsueh PR, Mendes RE, et al. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raoofi S, Pashazadeh Kan F, Rafiei S, et al. Global prevalence of nosocomial infection: A systematic review and meta-analysis. PLoS One 2023; 18:e0274248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Wang Y, Fan X, et al. Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study. Medicine (Baltimore) 2015; 94:e1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med 1998; 37:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudiol C, Royo-Cebrecos C, Laporte J, et al. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirology 2016; 21:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kara Ö, Zarakolu P, Aşçioğlu S, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (Lond) 2015; 47:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tofas P, Samarkos M, Piperaki ET, et al. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. Diagn Microbiol Infect Dis 2017; 88:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurora A, Le TD, Akers KS, et al. Recurrent bacteremia: A 10-year retrospective study in combat-related burn casualties. Burns 2019; 45:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am 2016; 63:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salsgiver EL, Fink AK, Knapp EA, et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 2016; 149:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crull MR, Somayaji R, Ramos KJ, et al. Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clin Infect Dis 2018; 67:1089.
          </a>
         </li>
         <li class="breakAll">
          Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost FJ, Nazareth DS, Charman SC, et al. Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data. Ann Am Thorac Soc 2019; 16:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro CMP, Higgs MG, Muhlebach MS, et al. Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. Int J Mol Sci 2023; 24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998; 26:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renders NH, Sijmons MA, van Belkum A, et al. Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol 1997; 148:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver A, Cantón R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogardt M, Hoboth C, Schmoldt S, et al. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 2007; 195:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007; 61:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise PA, Gonzalez M, Alekseeva I, et al. Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU. JAC Antimicrob Resist 2021; 3:dlaa129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slekovec C, Robert J, van der Mee-Marquet N, et al. Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012-2013 study. Eur J Clin Microbiol Infect Dis 2019; 38:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen BG, Jacobsen T, Eriksen HM, et al. An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs. Clin Infect Dis 2007; 44:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan A, Wolfenden LL, Song X, et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa respiratory tract infections associated with contaminated ultrasound gel used for transesophageal echocardiography - Michigan, December 2011-January 2012. MMWR Morb Mortal Wkly Rep 2012; 61:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prestel C, Moulton-Meissner H, Gable P, et al. Dialysis Water Supply Faucet as Reservoir for Carbapenemase-Producing Pseudomonas aeruginosa. Emerg Infect Dis 2022; 28:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallin M, Deplano A, Roisin S, et al. Pseudo-outbreak of extremely drug-resistant pseudomonas aeruginosa urinary tract infections due to contamination of an automated urine analyzer. J Clin Microbiol 2012; 50:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020; 81:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care 2020; 10:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luyt CE, Sahnoun T, Gautier M, et al. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care 2020; 10:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest 2020; 50:e13319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Che Yusof R, Norhayati MN, Mohd Azman Y. Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: a systematic review and meta-analysis. PeerJ 2023; 11:e15265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bongiovanni M, Barda B. Pseudomonas aeruginosa Bloodstream Infections in SARS-CoV-2 Infected Patients: A Systematic Review. J Clin Med 2023; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng QX, Ong NY, Lee DYX, et al. Trends in Pseudomonas aeruginosa (P. aeruginosa) Bacteremia during the COVID-19 Pandemic: A Systematic Review. Antibiotics (Basel) 2023; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratnam S, Hogan K, March SB, Butler RW. Whirlpool-associated folliculitis caused by Pseudomonas aeruginosa: report of an outbreak and review. J Clin Microbiol 1986; 23:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maniatis AN, Karkavitsas C, Maniatis NA, et al. Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Clin Infect Dis 1995; 21:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon RS, Sydnor CH 4th. Puncture wound pseudomonal osteomyelitis of the foot. J Foot Ankle Surg 1993; 32:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman NA, Levitsky S, Mammana R. Acute endocarditis in drug addicts: surgical treatment for multiple valve infection. J Am Coll Cardiol 1984; 4:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shekar R, Rice TW, Zierdt CH, Kallick CA. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago. J Infect Dis 1985; 151:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Asperen IA, de Rover CM, Schijven JF, et al. Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. BMJ 1995; 311:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan MK, Chan PC, Cheng IP, et al. Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment. Nephrol Dial Transplant 1989; 4:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CY, Chu WL, Wan KM, et al. Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment. Perit Dial Int 1998; 18:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis 1993; 148:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288.
          </a>
         </li>
         <li class="breakAll">
          COVID-19 US Impact on Antimicrobial Resistance. Centers for Disease Control and Prevention, 2022. Available at: https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf (Accessed on November 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36:2046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masuda N, Gotoh N, Ishii C, et al. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1:i29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai H, Kim J, Kim J, et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aires JR, Köhler T, Nikaido H, Plésiat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999; 43:2624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Kievit TR, Parkins MD, Gillis RJ, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003; 47:3202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hocquet D, Bertrand X, Köhler T, et al. Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrob Agents Chemother 2003; 47:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mah TF, Pitts B, Pellock B, et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokoyama K, Doi Y, Yamane K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 2003; 362:1888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11 Suppl 4:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talebi-Taher M, Majidpour َ, Gholami A, et al. Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran. J Infect Dev Ctries 2016; 10:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis 2018; 67:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrissey I, Hackel M, Badal R, et al. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013; 6:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moghnieh RA, Kanafani ZA, Tabaja HZ, et al. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis 2018; 18:e379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalili Y, Memar MY, Farajnia S, et al. Molecular epidemiology and carbapenem resistance of Pseudomonas aeruginosa isolated from patients with burns. J Wound Care 2021; 30:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YL, Ko WC, Hsueh PR. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019. Antimicrob Agents Chemother 2022; 66:e0200021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sader HS, Mendes RE, Arends SJR, et al. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Int J Antimicrob Agents 2023; 61:106744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez A, Gato E, Pérez-Llarena J, et al. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother 2019; 74:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sader HS, Carvalhaes CG, Shortridge D, Castanheira M. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020. Eur J Clin Microbiol Infect Dis 2022; 41:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DJ, Miller B, Marfatia R, Drew R. Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation. Infect Control Hosp Epidemiol 2012; 33:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Bonine NG, Ye JM, et al. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections. BMC Infect Dis 2019; 19:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollack M, Taylor NS, Callahan LT 3rd. Exotoxin production by clinical isolates of pseudomonas aeruginosa. Infect Immun 1977; 15:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somerville G, Mikoryak CA, Reitzer L. Physiological characterization of Pseudomonas aeruginosa during exotoxin A synthesis: glutamate, iron limitation, and aconitase activity. J Bacteriol 1999; 181:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012; 109:5809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fick RB Jr, Sonoda F, Hornick DB. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Semin Respir Infect 1992; 7:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006; 103:8487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995; 96:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervin MA, Simpson DA, Smith AL, Lory S. Differences in eucaryotic cell binding of Pseudomonas. Microb Pathog 1994; 17:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben Mohamed F, Garcia-Verdugo I, Medina M, et al. A crucial role of Flagellin in the induction of airway mucus production by Pseudomonas aeruginosa. PLoS One 2012; 7:e39888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997; 94:12088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984; 45:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vishwanath S, Ramphal R, Guay CM, et al. Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa. Infect Immun 1988; 56:2218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saint-Criq V, Villeret B, Bastaert F, et al. Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway. Thorax 2018; 73:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffries JL, Jia J, Choi W, et al. Pseudomonas aeruginosa pyocyanin modulates mucin glycosylation with sialyl-Lewis(x) to increase binding to airway epithelial cells. Mucosal Immunol 2016; 9:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer-Hamblett N, Ramsey BW, Kulasekara HD, et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis 2014; 59:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manos J, Hu H, Rose BR, et al. Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2013; 32:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raivio TL, Ujack EE, Rabin HR, Storey DG. Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients. Infect Immun 1994; 62:3506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hancock RE, Mutharia LM, Chan L, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983; 42:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145 ( Pt 6):1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucher JC, Yu H, Mudd MH, Deretic V. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 1997; 65:3838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pier GB, Meluleni G, Neuger E. A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun 1992; 60:4768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfgang MC, Jyot J, Goodman AL, et al. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A 2004; 101:6664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tager AM, Wu J, Vermeulen MW. The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis. Am J Respir Cell Mol Biol 1998; 19:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finck-Barbançon V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Solh AA, Hattemer A, Hauser AR, et al. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cillóniz C, Dominedò C, Torres A. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. Crit Care 2019; 23:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman LR, D'Argenio DA, MacCoss MJ, et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hao S, Yang D, Zhao L, et al. EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003; 52:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995; 155:2029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012; 366:1978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman LR, Déziel E, D'Argenio DA, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2006; 103:19890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDaniel MS, Schoeb T, Swords WE. Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections. Infect Immun 2020; 88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan MW, Rahme LG, Sternberg JA, et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A 1999; 96:2408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahajan-Miklos S, Tan MW, Rahme LG, Ausubel FM. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell 1999; 96:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath S, Kapatral V, Chakrabarty AM. Cellular function of elastase in Pseudomonas aeruginosa: role in the cleavage of nucleoside diphosphate kinase and in alginate synthesis. Mol Microbiol 1998; 30:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumoto T, Tateda K, Furuya N, et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 1998; 47:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso B, Fernández-Barat L, Di Domenico EG, et al. Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia. BMC Infect Dis 2020; 20:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman M, Bryan R, Rajan S, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998; 66:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake D, Montie TC. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J Gen Microbiol 1988; 134:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora SK, Neely AN, Blair B, et al. Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections. Infect Immun 2005; 73:4395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balloy V, Verma A, Kuravi S, et al. The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 2007; 196:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleiszig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun 1996; 64:2288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawa T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J Intensive Care 2014; 2:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagener BM, Anjum N, Christiaans SC, et al. Exoenzyme Y Contributes to End-Organ Dysfunction Caused by Pseudomonas aeruginosa Pneumonia in Critically Ill Patients: An Exploratory Study. Toxins (Basel) 2020; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balachandran P, Dragone L, Garrity-Ryan L, et al. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J Clin Invest 2007; 117:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004; 72:7012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burrows LL. Pseudomonas aeruginosa twitching motility: type IV pili in action. Annu Rev Microbiol 2012; 66:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbas HA, Shaldam MA, Eldamasi D. Curtailing Quorum Sensing in Pseudomonas aeruginosa by Sitagliptin. Curr Microbiol 2020; 77:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saqr AA, Aldawsari MF, Khafagy ES, et al. A Novel Use of Allopurinol as A Quorum-Sensing Inhibitor in Pseudomonas aeruginosa. Antibiotics (Basel) 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morello E, Saussereau E, Maura D, et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 2011; 6:e16963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Wan C, Yu B, et al. Prophylactic and therapeutic protection of human IgG purified from sera containing anti-exotoxin A titers against pneumonia caused by Pseudomonas aeruginosa. Hum Vaccin Immunother 2019; 15:2993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson CM, Kobe BN, Schmitt DM, et al. Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections. Bioengineered 2015; 6:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shippy DC, Fadl AA. Immunological characterization of a gidA mutant strain of Salmonella for potential use in a live-attenuated vaccine. BMC Microbiol 2012; 12:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Göcke K, Baumann U, Hagemann H, et al. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol 2003; 37:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004; 22:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rello J, Krenn CG, Locker G, et al. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit Care 2017; 21:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Divithotawela C, Pham A, Ledger EL, et al. Treatment of life-threatening Pseudomonas aeruginosa infection by pheresis of inhibitory antibodies. J Heart Lung Transplant 2020; 39:87.
          </a>
         </li>
         <li class="breakAll">
          Pseudomonas Genome DB. https://www.pseudomonas.com/ (Accessed on September 08, 2021).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3142 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7704834" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The survival and recovery of Pseudomonas aeruginosa and its effect upon salmonellae in water: methodology to test bottled water in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4999114" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pseudomonas aeruginosa: growth in distilled water from hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6402527" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6794372" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pseudomonas corneal ulcers associated with soft contact-lens wear.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9636877" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31767041" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31767041" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31010862" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36706112" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Global prevalence of nosocomial infection: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559260" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9932631" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27417156" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26024284" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28529091" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30385059" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recurrent bacteremia: A 10-year retrospective study in combat-related burn casualties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27469176" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Background and Epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15687313" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26203598" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29534149" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29534149" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319678" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36902441" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727757" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9765823" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10818002" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17152010" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17515861" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10432077" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34223078" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3927867" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pseudomonas bacteremia. Retrospective analysis of 410 episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10362409" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9661018" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3903939" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30826996" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012-2013 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304450" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12529462" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513528" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pseudomonas aeruginosa respiratory tract infections associated with contaminated ultrasound gel used for transesophageal echocardiography - Michigan, December 2011-January 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36148936" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dialysis Water Supply Faucet as Reservoir for Carbapenemase-Producing Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22219304" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pseudo-outbreak of extremely drug-resistant pseudomonas aeruginosa urinary tract infections due to contamination of an automated urine analyzer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32473235" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Co-infections in people with COVID-19: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32745596" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32894364" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33230710" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32535894" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bloodstream infections in critically ill patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37128208" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36983256" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pseudomonas aeruginosa Bloodstream Infections in SARS-CoV-2 Infected Patients: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36830319" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Trends in Pseudomonas aeruginosa (P. aeruginosa) Bacteremia during the COVID-19 Pandemic: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3082930" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Whirlpool-associated folliculitis caused by Pseudomonas aeruginosa: report of an outbreak and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562759" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10471620" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Severe community-acquired pneumonia. Risk factors and follow-up epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7902753" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Puncture wound pseudomonal osteomyelitis of the foot.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6481010" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Acute endocarditis in drug addicts: surgical treatment for multiple valve infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3918121" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8520277" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2516614" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pseudomonas peritonitis in CAPD patients: characteristics and outcome of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600121" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9932663" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214956" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7811859" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573805" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573805" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1329641" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925544" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19675016" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Has the era of untreatable infections arrived?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158744" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925552" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543738" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353623" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14506031" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12760863" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11294736" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Emerging mechanisms of fluoroquinolone resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12499208" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14628055" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14667745" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953020" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27367008" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30052813" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24287460" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30292478" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33573489" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Molecular epidemiology and carbapenem resistance of Pseudomonas aeruginosa isolated from patients with burns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34807753" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36738849" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Comparative activity of newerβ-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30753505" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34657213" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparative activity of newerβ-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37666449" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561714" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31412809" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/404244" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Exotoxin production by clinical isolates of pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9973331" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Physiological characterization of Pseudomonas aeruginosa during exotoxin A synthesis: glutamate, iron limitation, and aconitase activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9421308" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451929" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Decade-long bacterial community dynamics in cystic fibrosis airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1475541" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687478" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593606" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7536882" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Differences in eucaryotic cell binding of Pseudomonas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22768318" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A crucial role of Flagellin in the induction of airway mucus production by Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9342367" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6429045" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3137161" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28790180" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26555707" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Pseudomonas aeruginosa pyocyanin modulates mucin glycosylation with sialyl-Lewis(x) to increase binding to airway epithelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24863401" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23832143" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8039921" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Association between transcript levels of the Pseudomonas aeruginosa regA, regB, and toxA genes in sputa of cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6413410" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411261" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9284161" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1398987" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A murine model of chronic mucosal colonization by Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8300217" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084751" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8612275" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9038346" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727055" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9761762" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8539601" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25425629" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9302017" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22080633" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Clinical outcomes of type III Pseudomonas aeruginosa bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30850010" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16121184" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Aminoglycoside antibiotics induce bacterial biofilm formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34066609" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12909647" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827991" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7636254" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607135" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172450" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31932329" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10051655" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9989496" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988471" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Cellular function of elastase in Pseudomonas aeruginosa: role in the cleavage of nucleoside diphosphate kinase and in alginate synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9568995" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33261585" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9423837" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3141566" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Flagella, motility and invasive virulence of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972536" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Role of motility and flagellin glycosylation in the pathogenesis of Pseudomonas aeruginosa burn wound infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17570117" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8675339" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11372029" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25520826" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32512716" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Exoenzyme Y Contributes to End-Organ Dysfunction Caused by Pseudomonas aeruginosa Pneumonia in Critically Ill Patients: An Exploratory Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17235393" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089663" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15557624" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22746331" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Pseudomonas aeruginosa twitching motility: type IV pili in action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32020464" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Curtailing Quorum Sensing in Pseudomonas aeruginosa by Sitagliptin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34827323" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : A Novel Use of Allopurinol as A Quorum-Sensing Inhibitor in Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21347240" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31116632" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Prophylactic and therapeutic protection of human IgG purified from sera containing anti-exotoxin A titers against pneumonia caused by Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25617059" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23194372" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Immunological characterization of a gidA mutant strain of Salmonella for potential use in a live-attenuated vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12832121" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15040936" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28159015" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31718874" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Treatment of life-threatening Pseudomonas aeruginosa infection by pheresis of inhibitory antibodies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
